| Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer’s disease risk genes J Schwartzentruber, S Cooper, JZ Liu, I Barrio-Hernandez, E Bello, ... Nature genetics, 1-11, 2021 | 327 | 2021 |
| ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts S Valletta, H Dolatshad, M Bartenstein, BH Yip, E Bello, S Gordon, Y Yu, ... Oncotarget 6 (42), 44061, 2015 | 75 | 2015 |
| CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q) E Bello, A Pellagatti, J Shaw, C Mecucci, R Kušec, S Killick, A Giagounidis, ... British journal of haematology 171 (2), 210-214, 2015 | 23 | 2015 |
| Robust temporal map of human in vitro myelopoiesis using single-cell genomics C Alsinet, MN Primo, V Lorenzi, E Bello, I Kelava, CP Jones, ... Nature communications 13 (1), 1-17, 2022 | 17 | 2022 |
| Screening for functional transcriptional and splicing regulatory variants with GenIE SE Cooper, J Schwartzentruber, E Bello, EL Coomber, AR Bassett Nucleic acids research 48 (22), e131-e131, 2020 | 9 | 2020 |
| L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del (5q) myelodysplastic syndrome patients E Bello, J Kerry, S Singh, BH Yip, R Kušec, S Killick, S Raynaud, ... haematologica 103 (11), e496-e500, 2018 | 5 | 2018 |
| An integrated multi-omics-analysis provides mechanistic insight into the process of iPSC-to-neuron reprogramming. MR Kotter, K Karim, N Patikas, S Cooper, E Bello, E Metzakopian, ... GLIA 69, E43-E43, 2021 | | 2021 |
| Pathophysiology and treatment of myelodysplasia with del (5q) E Bello University of Oxford, 2017 | | 2017 |
